This study is currently not recruiting new participants. Add it to your favourites and check back later.
Clinical Trial

Treatment of Prostate Cancer

Study Description

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Biological - nivolumab

Specified dose on specified days

Drug - docetaxel

Specified dose on specified days

Drug - enzalutamide

Specified dose on specified days

Drug - rucaparib

Specified dose on specified days

Drug - prednisone

Specified dose on specified days

Additional Information

Official Study Title

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Clinical Trial ID

NCT03338790

ParticipAid ID

nel3Jd